Journal article icon

Journal article

Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial

Abstract:

INTRODUCTION: Non-alcoholic steatohepatitis (NASH) is now the commonest cause of chronic liver disease. Despite this, there are no universally accepted pharmacological therapies for NASH. Liraglutide (Victoza), a human glucagon-like peptide-1 (GLP-1) analogue, has been shown to improve weight loss, glycaemic control and liver enzymes in type 2 diabetes. There is currently a lack of prospective-controlled studies investigating the efficacy of GLP-1 analogues in patients with NASH. METHODS AND ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


Publisher:
BMJ Publishing Group
Journal:
BMJ Open More from this journal
Publication date:
2013-11-04
Acceptance date:
2013-10-03
DOI:
EISSN:
2044-6055
Language:
English
Keywords:
Pubs id:
pubs:438909
UUID:
uuid:fd01c6ac-8c52-44b5-ba15-1f31eb670fd3
Local pid:
pubs:438909
Source identifiers:
438909
Deposit date:
2014-08-28

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP